IACT Health

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Atopic dermatitis (eczema)2 trials
• Chronic rhinosinusitis with nasal polyps1 trial
• Colorectal cancer1 trial
• Diabetic foot ulcer1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Heart failure1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 34 trials
• Phase 1/21 trial
• Phase 21 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Terminated2 trials
• Recruiting1 trial

Lead sponsor

• Cadex Genomics1 trial
• Energenesis Biomedical Co., Ltd.1 trial
• Galera Therapeutics, Inc.1 trial
• Incyte Corporation1 trial
• Inventiva Pharma1 trial
• and 4 more

Running trials

• Recruiting

  A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

  NCT05930210· Phase 3· Energenesis Biomedical Co., Ltd.· Source

  Contact: Joseph Surber, Dr.

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

• Active, not recruiting

  Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

  NCT04959448· Regeneron Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Diabetic foot ulcer1 recruiting

Closed trials

• Completed

  Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

  NCT05456529· Phase 3· Incyte Corporation· Source

• Completed

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Vifor (International) Inc.· Source

• Terminated

  Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

  NCT04476797· Phase 1/2· Galera Therapeutics, Inc.· Source

• Terminated

  A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

  NCT04032704· Phase 2· Seagen Inc.· Source

• Completed

  Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

  NCT03892096· Cadex Genomics· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source